Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Warner

Orthopaedic Surgery Hagerstown, MD Medical Doctor

NPI 1457562480 CMS profile 66012

11110 Medical Campus Rd, Suite 205, Hagerstown, MD 21742

Open in the dashboard

General payments

$2,736

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Warner of Hagerstown, MD is reported in the CMS Open Payments database as having received $2,736 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $299 16
2024 General $370 12
2023 General $333 8
2022 General $823 11
2021 General $189 10
2020 General $276 11
2019 General $446 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Warner
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Daniel Warner were reported at $299. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Daniel Warner Orthopaedic Surgery median Middle half National median
2019 $446 $644 $140–$2,844 $163
2020 $276 $312 $75–$1,860 $114
2021 $189 $520 $117–$2,495 $132
2022 $823 $598 $128–$2,731 $149
2023 $333 $461 $128–$2,264 $160
2024 $370 $497 $134–$2,475 $164
2025 $299 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Linvatec Corporation $982 8 payments
  2. ViiV Healthcare Company $472 21 payments
  3. Ferring Pharmaceuticals Inc. $173 9 payments
  4. Bioventus LLC $152 6 payments
  5. Dynasplint Systems Inc. $106 1 payment
  6. Stryker Corporation $96 3 payments
  7. Zimmer Biomet Holdings, Inc. $74 1 payment
  8. Flexion Therapeutics, Inc. $63 3 payments
  9. Smith+Nephew, Inc. $55 4 payments
  10. ERMI Inc. $47 2 payments
  11. Other $516 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,225 84 payments
  2. Travel and Lodging $512 2 payments
Products named General payments · program years 2019–2025
  1. LINVATEC SHOULDER ARTHROSCOPY $739 4 payments
  2. HALL POWER $587 4 payments
  3. LIVATEC KNEE PRESERVATION SYSTEM $451 1 payment
  4. EUFLEXXA $173 9 payments
  5. ALLOGRAFT TISSUE $172 4 payments
  6. BIOBRACE 23MM $172 1 payment
  7. DOVATO $120 1 payment
  8. CABENUVA $115 5 payments
  9. Dynasplint $106 1 payment
  10. LINVATEC ARTHROSCOPY $102 1 payment
  11. Other $1,567 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

736

Median for Orthopedic Surgery: 203

Drug cost

$7,776

Median for Orthopedic Surgery: $1,433

Branded share of claims

24%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Er Diclofenac Sodium Brand 101 $2,973
Celecoxib Generic 113 $2,280
Meloxicam Generic 243 $777
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 52 $409
Ibuprofen Generic 24 $307
Tramadol Hcl Generic 93 $271
Acetaminophen-Codeine Acetaminophen With Codeine Brand 24 $220
Oxycodone Hcl Generic 36 $177
Naproxen Generic 17 $152
Gabapentin Generic 21 $132

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$330,218

Of which drugs: $39,682

Medicare patients

1,115

Average age 74

Services billed

7,717

727 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Depression 29%
Ischemic heart disease 28%
Chronic kidney disease 20%
COPD 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 50 65 $26,083
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 16 1,320 $6,832
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 15 30 $2,626
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 362 2,192 $1,626

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
  • ViiV Healthcare Company $120
$120 — —
CABENUVA
  • ViiV Healthcare Company $83
$83 — —
RUKOBIA
  • ViiV Healthcare Company $22
$22 — —
Zilretta
  • Pacira Pharmaceuticals Incorporated $11
$11 — —
APRETUDE
  • ViiV Healthcare Company $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record